Abiopharma

🔍 Underwood Peter C (Executive)

Company: Fortive Corp (FTV)

Report Date: 2026-05-04

Detailed Transactions and Holdings:

• Acquired 47,557 shares of Common Stock at $28.92 per share (Direct)
  Date: 2026-05-04 | Code: M | equity_swap_involved: 0 | shares_owned_after: 135,337.00 | transaction_form_type: 4
• Sold 47,557 shares of Common Stock at $60.81 per share (Direct)
  Date: 2026-05-04 | Code: S | equity_swap_involved: 0 | shares_owned_after: 87,780.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 47,557 shares of Employee Stock Option (Right to Buy) at $28.92 per share (Derivative)
  Date: 2026-05-04 | Code: M | Expires: 2026-05-15 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F2

Footnotes:

• F1: The price reported in Table I, Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.68 to $61.00. The Reporting Person undertakes to provide to the Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
• F2: Prior to the separation of the Issuer from Danaher Corporation ("Danaher") on July 2, 2016 (the "Separation"), one-fifth of the stock options issued by Danaher on May 15, 2016 ("2016 Danaher Options") to the Reporting Person became exercisable on each of the first five anniversaries of the grant date. In connection with the Separation, the 2016 Danaher Options that remained outstanding as of July 2, 2016 were converted into stock options to purchase 77,361 shares of the Issuer's common stock with identical vesting schedule. In addition, the total number of stock options and the exercise price reflect anti-dilution adjustments applied as a result of the spin-off of Vontier Corporation from the Issuer on October 9, 2020 and the spin-off of Ralliant Corporation from the Issuer on June 28, 2025.